Clinical development of denovoSkin™

denovoSkin™ is being clinically tested for burns and reconstructive indications in children and adults. It is investigational and not yet approved.

From first-in-human to Phase III

The standard of care in burn, plastic and reconstructive surgery, autografting, is limited by donor site shortage and can leave permanent scars. The denovoSkin™ programme compares the graft with autografting to establish safety and efficacy.

Sources: cutiss.swiss, UZH News, January 2026

Phase I

Safety, first in human

Completed with a five-year follow-up, with 10 paediatric patients at the University Children’s Hospital Zurich.

Phase II

Three randomised, controlled trials

Adult and adolescent burns, paediatric burns, and reconstructive surgery at all ages, with denovoSkin™ compared to autografting on every patient (intra-patient control).

Phase III

Ongoing, randomised and controlled

Started in spring 2025 for severe burns in adults and adolescents, in burn centres across eight EU countries and Switzerland, to confirm safety and efficacy.

Compassionate use

Individual access

denovoSkin™ is also accessible under compassionate use.

For surgeons and burn centres

If your centre is interested in the clinical programme or in compassionate use, the CUTISS clinical team can share the current trial sites and criteria.

Contact the clinical team
Diagram of the denovoSkin process: stamp-sized biopsy, cell isolation, cell expansion with bio-banking possibility, tissue formation, denovoSkin

For patients and families

Recovering from a severe burn or preparing for reconstructive surgery raises many questions. This page explains what denovoSkin™ is. It is not medical advice.

What you should know

denovoSkin™ is a personalised skin graft grown from a small biopsy of the patient’s own healthy skin.

It is still being studied in clinical trials and is not yet approved, so it is not available as a standard treatment.

Participation in a trial is decided by the treating burn centre and depends on its criteria. Please speak with your surgical team first.

Ask a question